Skip to main content

Kadmon Holdings, Inc. (KDMN)

NASDAQ: KDMN · IEX Real-Time Price · USD
8.84 -0.05 (-0.56%)
Sep 24, 2021 9:57 AM EDT - Market open
Market Cap1.54B
Revenue (ttm)1.87M
Net Income (ttm)-113.36M
Shares Out171.97M
EPS (ttm)-0.66
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume296,037
Open8.86
Previous Close8.89
Day's Range8.84 - 8.90
52-Week Range3.15 - 9.20
Beta1.62
AnalystsStrong Buy
Price Target12.10 (+36.9%)
Est. Earnings DateNov 4, 2021

About KDMN

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD...

IndustryBiotechnology
IPO DateJul 27, 2016
Employees127
Stock ExchangeNASDAQ
Ticker SymbolKDMN
Full Company Profile

Financial Performance

In 2020, KDMN's revenue was $8.29 million, an increase of 62.67% compared to the previous year's $5.10 million. Losses were -$108.91 million, 77.5% more than in 2019.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for KDMN stock is "Strong Buy." The 12-month stock price forecast is 12.10, which is an increase of 36.88% from the latest price.

Price Target
$12.10
(36.88% upside)
Analyst Consensus: Strong Buy

News

KADMON HOLDINGS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequ...

NEW ORLEANS, Sept. 21, 2021 /PRNewswire/ -- Former Attorney General of Louisiana Charles C.

Other symbols:SNY
2 days ago - PRNewsWire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GTS, HRC, JMP, KDMN, FIBK; Shareholders are Encouraged to Co...

NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Triple-S Management Corporation (NYSE: GTS)  concerni...

Other symbols:FIBKGTSHRCJMP
3 days ago - PRNewsWire

SHAREHOLDER ALERT: WeissLaw LLP Reminds ECHO, KDMN, HRC, and DVCR Shareholders About Its Ongoing Investigations

NEW YORK, Sept. 17, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights o...

Other symbols:DVCRECHOHRC
6 days ago - PRNewsWire

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Kadmon Holdings, Inc. - KDMN

NEW YORK, Sept. 13, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Actio...

1 week ago - PRNewsWire

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kadmon Holdings, Inc.

NEW YORK, Sept. 9, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Kadmon Holdings, Inc. (NASDAQ: KDMN) and its board of directors concerning the proposed ac...

Other symbols:SNY
2 weeks ago - PRNewsWire

Kadmon Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Kadmon Holdings, Inc. ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Kadmon Holdings, Inc. (NASDAQ: KDMN) to Sanofi for $9.50 per share in cash is fair to...

2 weeks ago - Business Wire

Shareholder Alert: Ademi LLP investigates whether Kadmon Holdings, Inc. has obtained a Fair Price in its transaction ...

MILWAUKEE, Sept. 8, 2021 /PRNewswire/ -- Ademi LLP is investigating Kadmon (NASDAQ:KDMN), for possible breaches of fiduciary duty and other violations of law in its transaction with Sanofi.

2 weeks ago - PRNewsWire

Sanofi (SNY) to Buy Kadmon for $1.9B, Add cGVHD Drug Rezurock

Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business.

Other symbols:SNY
2 weeks ago - Zacks Investment Research

Why Kadmon Holdings Stock Is Rocketing Higher Today

Sanofi adds another bolt-on acquisition in what is turning out to be a busy year for the French pharma titan.

2 weeks ago - The Motley Fool

Sanofi to acquire Kadmon to further strengthen growth of transplant business

Dear recipient,Please note this is a corrected french version of the release which replaces the release sent on September 8 at 8.31 am Paris time where the word « … relutif» has been replaced with « …di...

2 weeks ago - GlobeNewsWire

Sanofi's $1.9 Billion Bet On Kadmon: What You Need to Know

Underlining the focus on inorganic growth, French pharma giant Sanofi (NASDAQ: SNY) announced a big-ticket acquisition just a month after another billion-dollar deal. Sanofi-Kadmon Deal Terms: Sanofi an...

Other symbols:SNY
2 weeks ago - Benzinga

France's Sanofi to buy U.S. biopharma firm Kadmon in $1.9 billion deal

French drugmaker Sanofi SA has agreed to buy U.S. biopharmaceutical company Kadmon Holdings Inc in a $1.9 billion deal, the companies said on Wednesday.

Other symbols:SNY
2 weeks ago - Reuters

Sanofi To Acquire Kadmon To Further Strengthen Growth of Transplant Business

Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two pr...

2 weeks ago - Accesswire

Kadmon Announces U.S. Availability of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Ver...

NEW YORK, NY / ACCESSWIRE / August 19, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets is now commercially available for shipment t...

1 month ago - Accesswire

5 Penny Stocks Analysts Say To Buy With Targets Up To 300%

Penny stocks to buy according to analysts with price targets up to 300% right now. The post 5 Penny Stocks Analysts Say To Buy With Targets Up To 300% appeared first on Penny Stocks to Buy, Picks, News ...

Other symbols:SBSENSVERBXBIO
1 month ago - PennyStocks

Implied Volatility Surging for Kadmon Holdings (KDMN) Stock Options

Investors need to pay close attention to Kadmon Holdings (KDMN) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

Kadmon Holdings, Inc. (KDMN) Reports Q2 Loss, Lags Revenue Estimates

Kadmon Holdings, Inc. (KDMN) delivered earnings and revenue surprises of 0.00% and -42.06%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Kadmon Provides Business Update and Reports Second Quarter 2021 Financial Results

NEW YORK, NY / ACCESSWIRE / August 5, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the second quarter of 2021. "The rece...

1 month ago - Accesswire

Kadmon Announces REZUROCK(TM) (belumosudil) Added to National Comprehensive Cancer Network(R) Clinical Practice Guide...

NEW YORK, NY / ACCESSWIRE / August 4, 2021 / Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced that the National Comprehensive Cancer Network® (NCCN) added REZUROCKTM (belumosudil) tablets to its NCCN...

1 month ago - Accesswire

Analysts Estimate Kadmon Holdings, Inc. (KDMN) to Report a Decline in Earnings: What to Look Out for

Kadmon Holdings, Inc. (KDMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

7 Penny Stocks To Buy According To Analysts With Targets Up To 316%

Analysts say these are penny stocks to buy. Do you agree?

Other symbols:NMTRPFMTSEEL
2 months ago - PennyStocks

Kadmon Announces Pivotal Trial Data Published in the Journal Blood for REZUROCK(TM) (Belumosudil) in Chronic Graft-Ve...

- REZUROCK is approved by the U.S. FDA for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy - NEW YORK, NY / ACCE...

2 months ago - Accesswire

Kadmon's REZUROCK Scores Quick FDA Win For Chronic Graft-Versus-Host Disease

Friday afternoon, the FDA approved Kadmon Holdings Inc's (NASDAQ: KDMN) REZUROCK to treat chronic graft-versus-host disease (cGVHD), a serious complication of transplant procedures. Formerly known as be...

2 months ago - Benzinga

U.S. FDA Grants Full Approval of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-H...

- REZUROCK is approved for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy - - Kadmon to Host Conference Call on...

2 months ago - Accesswire

KDMN FINAL DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Kadmon Holdings, Inc. Investors with Losses to Se...

NEW YORK, June 2, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kadmon Holdings, Inc. (NASDAQ: KDMN) between October 1, 2020 and Ma...

3 months ago - PRNewsWire